Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.47%
SPX
+0.40%
IXIC
+0.24%
FTSE
-0.20%
N225
-0.88%
AXJO
-0.49%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Recently from Cashu

publisher logo
Cashu

ImmunityBio Champions Innovation in Cancer Therapies Amidst Evolving Healthcare and Media Landscapes

2 days ago
publisher logo
Cashu

ImmunityBio Navigates Media Evolution to Enhance Public Perception and Engagement

4 days ago
publisher logo
Cashu

ImmunityBio's Innovative Strategies Amid Shifting Biotechnology and Media Landscapes

6 days ago

Key Stats

Market Cap
2.57B
Dividend Yield
0.00%
P/E Ratio
-6.28
EPS
-0.59
Revenue
14.74M
Avg. Volume
3.71M

About

What does IBRX do?
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
Sector
💻 Health Care
IPO
CEO
Employees
Headquarters
California, USA
Stocks
Health Care
ibrx
ImmunityBio
IBRX
-0.15 (-4.98%)
2.86
USD
At close at Jul 25, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials